a month ago
- Anthropic announces Claude Science, an AI workbench for scientists, aiming to accelerate scientific discovery and healthcare interventions.
- Anthropic plans to develop its own drugs, focusing on treatments for neglected diseases, which is a direct move into drug development by a frontier AI company.
- Experts note AI's broad application in drug discovery across all stages, but highlight challenges such as data gaps, the necessity of real-world experiments, and the long timeline for drug approval.
- Despite AI's potential to speed up research and suggest new drug ideas, no AI-designed drug has yet reached the market, with clinical trials and safety testing remaining slow and resource-intensive.
- Anthropic is actively hiring biologists and building wet labs, indicating commitment to its drug development ambitions, though specifics on targets and partnerships remain undisclosed.